Technology | Lung Cancer | August 28, 2017

20/20 GeneSystems Launches AI-Based Lung Cancer Detection Technology in China

Platform represents first machine learning approach available to hospitals to aid in evaluating ambiguous pulmonary nodules

20/20 GeneSystems Launches AI-Based Lung Cancer Detection Technology in China

August 28, 2017 — 20/20 GeneSystems Inc. recently released in China what is believed to be the world’s first machine learning algorithm commercialized for use in conjunction with blood tests to aid in the early detection of lung cancer. The cloud-accessible software, marketed in China by MyBioMed Ltd., is expected to be utilized over the next six months by at least 20 hospitals in five or more cities to help in distinguishing between benign versus malignant pulmonary nodules following computed tomography (CT) imaging.

The algorithm, built and validated with data from over 1,000 patients tested at the Tianjin Cancer Institute combines the values of biomarker — tumor-associated proteins in the blood — and individual patient characteristics such as their age, smoking status and nodule size. It could potentially increase the number of cancers detected by more than 50 percent over current methods. Artificial neural networks are incorporated to permit continuous improvements as more data is acquired over time.

Lung cancer is a significant burden in China as more than half of adult men in that country are current or former smokers and heavy air pollution further contributes to the disease. "Lung cancer in China has a very high disease incidence and the current solution is to do early screening which often leads to good outcomes at a low cost,” said Yilong Wu, M.D. chair of the Chinese Society of Clinical Oncology and himself a chest surgeon and lung cancer expert. “Low-dose CT (LDCT) screening has been recognized worldwide as an approach to reduce lung cancer mortality but these scans uncover many nodules that turn out to be benign, and unneeded biopsies and surgery can be dangerous to many patients,” he added. “I am very optimistic about the approach introduced by 20/20 and MBM of adding bioinformatics and artificial intelligence methods to improve the sensitivity and specificity of detection and look forward to seeing continued expansion of their data sets and confirmatory studies."

20/20’s cloud-based lung nodule assessment software is the company’s first product marketed using a software-as-a-service (SaaS) revenue model, according to 20/20 CEO Jonathan Cohen.

For more information: www.2020gene.com

Related Content

Philips Launches IntelliSpace Discovery Research Platform at RSNA
Technology | Artificial Intelligence | November 20, 2018
Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Nov. 25-30 in Chicago, Royal Philips...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...
Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
ContextVision Introduces AI-Powered Image Enhancement for Digital Radiography
Technology | Artificial Intelligence | November 09, 2018
With the integration of deep learning technology, ContextVision takes digital radiography to new levels with its latest...